Milgamma Protekt (Benfotiamine)

Benfotiamine, the active ingredient in Milgamma Protekt, is a thiamine derivative presented as an oral supplement for oral use. It is used to support peripheral nerve health, assist in the management of diabetic complications, and provide nutritional supplementation for thiamine deficiency.

GNH USA supplies Milgamma Protekt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milgamma Protekt (benfotiamine) acts on metabolic pathways related to carbohydrate processing and advanced glycation end‑product formation. - Peripheral nerve health: supports nerve function and may alleviate symptoms of neuropathy. - Diabetic complications: used as an adjunct to help manage metabolic disturbances associated with diabetes. - Thiamine deficiency: provides nutritional supplementation to restore adequate vitamin B1 levels.

Benfotiamine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal discomfort: mild nausea or abdominal upset. - Headache: transient and usually mild. - Skin rash: occasional pruritic erythema. - Dizziness: brief episodes reported. - Fatigue: occasional feeling of tiredness.

Serious or Rare Side Effects: - Hypersensitivity reactions: including angioedema or anaphylaxis. - Hepatic enzyme elevation: rare cases of increased transaminases. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hematologic abnormalities: rare reports of leukopenia. - Cardiovascular events: isolated reports of arrhythmia.

Benfotiamine should be used with awareness of specific safety considerations. - Pregnancy: safety not established; use only if clearly needed and prescribed. - Breastfeeding: unknown safety profile; consider risk‑benefit before use. - Renal impairment: monitor renal function and adjust if clinically indicated. - Concomitant medications: review all drugs for potential interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Benfotiamine may interact with certain medications, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - None clinically significant: no major drug‑drug interactions have been documented.

Moderate Interactions (Monitor Closely): - High‑dose thiamine supplements: may lead to excess thiamine levels. - Alcohol consumption: can affect thiamine metabolism and reduce efficacy. - Diuretics: may increase urinary thiamine loss, necessitating monitoring. - Chemotherapy agents: observe for additive toxicity, especially neurotoxic regimens.